2. Neuronal Signaling Stem Cell/Wnt
  3. Notch
  4. Navicixizumab

Navicixizumab  (Synonyms: OMP-305B83; Anti-DLL4 Reference Antibody (navicixizumab))

Cat. No.: HY-P99377
COA
SDS
Technical Support

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer.

For research use only. We do not sell to patients.

CAS No. : 1638338-43-8

Size Price Stock Quantity
1 mg In-stock
5 mg Get quote
10 mg Get quote
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Navicixizumab Featured Recommendations:

Navicixizumab Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Navicixizumab (OMP-305B83) is a bispecific anti-VEGF and anti-DLL4 inhibitory antibody. Navicixizumab can combine with Paclitaxel (HY-B0015) for cancer research. Navicixizumab can be used in the research of ovarian, primary peritoneal, or fallopian tube cancer[1][2][3].

Isotype

Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity

Human
IC50 & Target

DLL4 & VEGFA
In Vitro

Navicixizumab (0-100 μM) reduces proliferation of human endothelial cells in the presence of hVEGF[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Navicixizumab Related Antibodies
In Vivo

Navicixizumab (15 mg/kg, once a week for 4 weeks) inhibits colon xenograft tumor growth[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Clinical Trial
Gene ID

54567  [NCBI] & 7422  [NCBI]

Accession
Application

ELISA, FACS, Functional assay
Conjugated

Unconjugated
Reconsititution

The product can be reconstituted/diluted with sterile PBS or saline.
Molecular Weight

145.83 kDa

CAS No.
Appearance

Liquid

Color

Colorless to light yellow

SMILES

[Navicixizumab]
Shipping

Shipping with dry ice.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Format
  • Human IgG2 kappa
Biological Activity
  • Immobilized Delta-like protein 4/DLL4 Protein, Human (HEK293, HY-P72972) can bind Navicixizumab. The EC50 for this effect is 20.88 ng/mL.
  • Immobilized VEGF165 Protein, Human (P.pastoris, HY-P7110) can bind Navicixizumab. The EC50 for this effect is 4.41 ng/mL.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Navicixizumab Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Navicixizumab1638338-43-8OMP-305B83Anti-DLL4 Reference Antibody (navicixizumab)NotchNavicixizumab (OMP-305B83) 是一种双特异性抗 VEGF 和抗 DLL4 抑制抗体。Navicixizumab 可以与紫杉醇结合用于癌症研究。Navicixizumab 可用于卵巢癌、原发性腹膜癌或输卵管癌的研究。Inhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Navicixizumab
Cat. No.:
HY-P99377
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (251 KB) Français - FR (251 KB) Deutsch - DE (251 KB) Norwegian - NO (251 KB) Español - ES (251 KB) Swedish - SV (251 KB) Italian - IT (251 KB) Portuguese - PT (251 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.